原始出處紀錄
重大申請已送件
Inhibrx 提交 ozekibart 用於常規軟骨肉瘤的 BLA
Inhibrx 於 2026 年 4 月向 FDA 提交 ozekibart 用於常規軟骨肉瘤的 BLA。該公司亦計劃於 2026 年下半年與 FDA 會面，討論 CRC 一線註冊性試驗，以及 ozekibart 用於四線 CRC 及難治性尤因氏肉瘤的潛在加速途徑。
關鍵事實
- 申報時間
- 2026年5月14日 下午08:04
- 事件
- 申請已送件
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 exhibit99103312026.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports First Quarter 2026 Financial Results San Diego, CA, May 14, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming Milestones • INBRX-106 ◦ In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combin